BF
RARE icon

BOK Financial’s Ultragenyx Pharmaceutical RARE Stock Holding History

BOK Financial’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-34
Closed -$1.23K – 1298
2025
Q1 		$1.23K Sell
34
-7,942
-100% -$330K ﹤0.01% 1160
2024
Q4 		$336K Buy
7,976
+382
+5% +$19K 0.01% 621
2024
Q3 		$407K Sell
7,594
-722
-9% -$36.8K 0.01% 604
2024
Q2 		$342K Buy
8,316
+1,580
+23% +$67.5K 0.01% 669
2024
Q1 		$316K Buy
+6,736
New +$318K 0.01% 629
2020
Q1 		– Sell
-13,188
Closed -$563K – 904
2019
Q4 		$563K Buy
+13,188
New +$544K 0.01% 675

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BOK Financial's RARE Position: Q2 2025 in Review

BOK Financial sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2025, closing a stake of 34 shares — an estimated $1.23K sold.

BOK Financial first reported a position in RARE in Q4 2019 and held it in 6 quarters. The position peaked at $563K in Q4 2019. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2025.

  • BOK Financial reported no remaining Ultragenyx Pharmaceutical position as of Q2 2025 after selling out during the quarter.
  • BOK Financial sold 34 Ultragenyx Pharmaceutical shares in Q2 2025, an estimated $1.23K.
  • BOK Financial first reported a position in Ultragenyx Pharmaceutical in Q4 2019 and held it in 6 quarters.
  • BOK Financial's Ultragenyx Pharmaceutical position peaked at $563K in Q4 2019.
  • 310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2025.

Based on BOK Financial's 13F filing for Q2 2025, filed 12 Aug 2025.